Oct 22 (Reuters) - Briacell Therapeutics Corp BCT.TO:
BRIACELL RECEIVES POSITIVE RECOMMENDATION FROM DATA SAFETY MONITORING BOARD (DSMB) FOR PHASE 3 STUDY IN METASTATIC BREAST CANCER
BRIACELL THERAPEUTICS CORP - PHASE 3 STUDY UNDER FDA FAST TRACK DESIGNATION BEING CONDUCTED
BRIACELL THERAPEUTICS CORP: POST REVIEW, DSMB RAISED NO SAFETY CONCERNS & RECOMMENDED STUDY CONTINUE WITHOUT MODIFICATIONS
Source text: ID:nGNXbLCGNb
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.